China SFDA Generics Report Acknowledges Industry And Regulator Have A Long Road Ahead
This article was originally published in PharmAsia News
Executive Summary
A rare government report criticizes practices of China’s generics industry and SFDA, officially highlighting well-recognized problems – from a lengthy registration process to a lack of pricing and bidding incentives – which need urgent attention.